Date: Feb 05, 2014 Author: press release Source: Company Data (
click here to go to the source)
 |
Baltimore, MD, February 5, 2014 -- Cerecor Inc., a clinical stage biopharmaceutical company developing prescription pharmaceuticals that work in the human nervous system and address the needs of underserved patient segments of major diseases, today announced that Blake Paterson, MD, CEO and Co-founder, will present at the 16th Annual BIO CEO & Investor Conference taking place February 10-11, 2014, in New York, NY. Dr. Paterson will provide an overview of the Company's lead candidate, CERC-301, a once daily, oral, adjunctive, selective NMDA receptor subunit 2B (NR2B) antagonist with the potential to be the first in a new class of rapidly acting antidepressants, which is currently in a Phase 2 study. In addition, Dr. Paterson will discuss Cerecor's COMT inhibitor platform for the treatment of cognitive impairment in conditions where loss of executive function is a key symptom. The presentation will take place Monday, February 10 at 10:30am ET.
About Cerecor
Cerecor Inc. is a privately held clinical stage biopharmaceutical company developing prescription pharmaceuticals that work in the human nervous system and which address the needs of underserved patient segments of major diseases. We are committed to the development of drugs that improve lives by applying our extensive knowledge and experience in central nervous system disorders. www.cerecor.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements." All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to the potential benefits and safety of CERC-301. Forward-looking statements are based upon management's current expectations and beliefs and are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results and events to differ materially from those indicated herein including, among others, risks and uncertainties relating to the completion and outcome of clinical trials. While Cerecor may update certain forward-looking statements from time to time, it specifically disclaims any obligation to do so, whether as a result of new information, future developments or otherwise. You are cautioned not to place undue reliance on any forward-looking statements.
Contact
MacDougall Biomedical Communications
Michelle Avery, 781.235.3060, mavery@macbiocom.com, or
Christine Labaree, 650.339.7533, clabaree@macbiocom.com
